Topically Delivered Minocycline Penetrates a Full-Thickness Burn Eschar and Reduces Tissue Bacterial Counts

Area of Science:

• Wound healing research
• Topical drug delivery systems
• Infectious disease management

Background:

• Skin injuries are prone to infections, with current treatments facing challenges in tissue penetration and systemic toxicity.
• Existing topical antimicrobial methods offer limited efficacy and short-lived action.
• Effective wound management requires improved strategies for delivering therapeutic agents directly to wound sites.

Purpose of the Study:

• To evaluate a new Platform Wound Device (PWD) for delivering ultrahigh concentrations of topical minocycline and lidocaine.
• To assess the efficacy of PWD-delivered minocycline against bacterial infections in wound models.
• To determine the effectiveness of PWD-delivered lidocaine in pain management for various wound types.

Main Methods:

• A porcine model was used, involving 56 burn wounds and 24 excisional wounds.
• Wounds were created on day 0 and debrided on day 3.
• The Platform Wound Device (PWD) was employed for topical delivery of minocycline and lidocaine.

Main Results:

• PWD with minocycline significantly reduced bacterial counts compared to silver sulfadiazine cream in methicillin-resistant Staphylococcus aureus-infected wounds (5.44 log CFU/g vs. 7.64 log CFU/g).
• Lidocaine delivered via PWD effectively relieved or eliminated pain in both burn and full-thickness excisional wounds.
• The PWD facilitated the delivery of ultrahigh antibiotic concentrations, enhancing wound bed preparation.

Conclusions:

• The Platform Wound Device (PWD) offers an effective method for delivering high concentrations of topical antimicrobials and analgesics.
• PWD-mediated delivery accelerates wound bed preparation by combating infection and managing pain.
• This technology presents a significant advancement in topical wound treatment strategies.